Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Dewhurst

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Gut|September 1, 1980
Weight loss in primary biliary cirrhosisG J Beckett, N Dewhurst, N D Finlayson, et al.
The Journal of Antimicrobial Chemotherapy|September 1, 1994
Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosisI N Simpson, J Finlay, D J Winstanley, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|December 9, 2010
Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practiceTony Antoniou, J M Raboud, C Diong, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Gut|September 1, 1980
Weight loss in primary biliary cirrhosisG J Beckett, N Dewhurst, N D Finlayson, et al.
The Journal of Antimicrobial Chemotherapy|September 1, 1994
Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosisI N Simpson, J Finlay, D J Winstanley, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|December 9, 2010
Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practiceTony Antoniou, J M Raboud, C Diong, et al.
Pageof 2